BriaCell Therapeutics Corp (NASDAQ:BCTX) Stock Breakout Alert: How to Trade Now?
BriaCell Therapeutics Corp (NASDAQ:BCTX) jumped 11%. Recently the company announced the open enrolment and recruitment in the collaborative Phase I/IIa combination study with Incyte.
The study seeks to assess BriaCell’s flagship candidate, Bria-IMT, in combination with Incyte retifinalimab checkpoint inhibitor and epacadostat IDPO1 inhibitor in advanced breast cancer treatment. In addition, the companies are conducting a non-exclusive collaboration clinical trial evaluating the impacts of the novel candidate’s combination.
As per the terms of the agreement, Incyte offers two compounds from its portfolio, including anti-PD-1 monoclonal antibody, retifanlimab, and IDO1 inhibitor epacadostat, to sue in combination with Bria-IMT in treating patients advanced breast cancer.
Previously the companies treated two patients in Phase I/IIa combination clinical trials after their collaboration commencing April 20219. Some of the patients were part of BriaCell’s latest survival data announcement. Since funding was secured, the company opted to open the collaborative study to recruitment and enrolment. So in the coming days, BCTX is a stock to watch.
Market Reaction:
On Wednesday, BCTX stock leaped 11.30% at $4.93 with more than 1 million shares, compared to its average volume of 4.28 million shares. The stock has moved within a range of $4.3700 – 5.0800 after opening the trade at $4.50. Over the past 52-week, the stock has been trading within a range of $2.8100 – 9.0000.
